Literature DB >> 4558903

Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol.

M Perez-Reyes, M C Timmons, M A Lipton, K H Davis, M E Wall.   

Abstract

A microsuspension of Delta(9)-tetrahydrocannabinol and of its metabolic derivative 11-OH-Delta(9)-tetrahydrocannabinol has been prepared with 25 percent human serum albumin as the vehicle. Intravenous infusion of this preparation to humans indicates that both tetrahydrocannabinols are equally potent in producing the typical marihuana-like pschological and physiological effects.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4558903     DOI： 10.1126/science.177.4049.633

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  26 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

Review 2.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

4.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

5.  Intravenous marijuana syndrome.

Authors:  D Brandenburg; R Wernick
Journal:  West J Med       Date:  1986-07

6.  A comparison of the pharmacological activity of delta 9-tetrahydrocannabinol and its monohydroxylated metabolites in man.

Authors:  M Perez-Reyes; M C Timmons; M A Lipton; H D Christensen; K H Davis; M E Wall
Journal:  Experientia       Date:  1973-08-15

7.  A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol.

Authors:  M Perez-Reyes; M C Timmons; K H Davis; E M Wall
Journal:  Experientia       Date:  1973-11-15

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

10.  Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.

Authors:  L Lemberger; R Martz; B Rodda; R Forney; H Rowe
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.